— Disease indication: metabolic disorders including insulin resistance and diabetic nephropathy
Drug format: chemically modified synthetic microRNA (miRNA)
Drug class: first-in-class for metabolic disease
Research stage and Preliminary data:
Target: miR-29 mimics can increase the gene expressio…
— Technology Description
Researchers at Washington University in St. Louis and their colleagues have developed positron emission tomography (PET) tracers with high affinity for sigma-1 receptors. Sigma receptors have two subtypes, sigma-1 and sigma-2. Sigma-1 has high expression in the limbic and mo…
— Technology Description
Researchers at Washington University in St. Louis have developed a method to create designer stem cells which provide a safer, more effective cell therapy approach to treating disease. Cell-based regenerative therapies could potentially be used to treat many diseases and res…
— Prof. Timothy Miller and colleagues have identified a motor neuron-specific, drug responsive microRNA (miR-218) that reflects the pathology of amyotrophic lateral sclerosis (ALS). This biomarker could be a target for therapeutic intervention or a proxy for motor neuron health and survival, including…
— Analyte: Small proline rich protein 3 (gene SPRR3)
Antibody codes: 3E9.1 (4587), 4G3.1 (4563), and 2F10.2 (4604)
Publications:
| Name | # Summaries | Author | Action |
|---|---|---|---|
| 15 | |||
| 13 | |||
| 1 | |||
| 15 | |||
| 26 | |||
| 14 | |||
| 14 |
Creating...
